Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

“We are thrilled to reach this crucial milestone in our clinical program”, said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The results of this Phase 2b study show promising reductions ...
Nasdaq

Sagimet Biosciences Reports Successful Phase 3 Results for Denifanstat in Moderate to Severe Acne and Initiates Phase 1 Trial for TVB-3567

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...
Seeking Alpha

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...
Seeking Alpha

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and ...
Nasdaq

Ascletis Reports Positive Phase 3 Safety Results Of Denifanstat In Moderate-to-Severe Acne

(RTTNews) - Ascletis Pharma Inc. (HKEX: 1672) today announced positive topline results from its Phase 3 study for Denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor for ...

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combinationPhase 2 trial of denifanstat/resmetirom ...